Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-04-02 DOI:10.1038/s41571-024-00889-9

Peter Sidaway

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Pembrolizumab 联合放化疗对局部晚期宫颈癌有效

局部晚期宫颈癌患者通常会接受化学放疗（CRT）作为一线疗法，但这种方法通常不能治愈疾病。现在，ENGOT-cx11/GOGG-3047/KEYNOTE-A18 III 期试验的数据表明，在 CRT 中加入抗 PD-1 抗体 pembrolizumab 可以降低这种情况下疾病进展的风险。共有1060名FIGO IB2-IIB期或III-IVA期宫颈鳞状细胞癌、腺癌或腺鳞癌结节阳性的妇女被随机分配（1:1）接受CRT加pembrolizumab或安慰剂治疗，然后接受pembrolizumab或安慰剂维持治疗。无进展生存期（PFS）和总生存期（OS）为共同主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.